LipoPhos Forte

The Possible Benefits of LipoPhos Forte :

• Supports healthy levels of total, HDL and LDL cholesterol, and serumtriglycerides
• Can help normalize reactive platelet aggregation, and cardiovascular risk ratios
• Supports healthy peripheral brain circulation
• May help control sub-optimal vascular wall tissue accumulation
• Supports normal levels of exercise tolerance

LipoPhos Forte offers primary support for the health of the circulatory system. An optimal circulatory function can benefit every cell in the body. The function and structural integrity of cells depends utterly on good circulation, for the delivery of life-giving nutrients and for the removal of metabolic wastes. Cells in the liver, the heart, the brain, the immune system - in fact, all cells in the body - cannot thrive without good circulation. One basic key to good circulation is healthy lipid levels.

LipoPhos Forte is a blend of highly refined phospholipids (phosphatides). The phospholipids in Lipoflow Forte are 70% phosphatidylcholine, and 30% phosphatidylinositol and phosphatidylethanolamine. It also contains polyunsaturated fatty acids, primarily the essential linoleic and linolenic fatty acids. LipoPhos Forte is made through a proprietary and costly procedure from natural soy lecithin, but it is not the same as soy lecithin or phospholipids available in pill form. The special process used to make EPL allows it to spontaneously form microscopic cellular structures whose walls are very similar in construction to the actual cell membranes found in the human body. These are the components that form the outer membrane of every living cell.

Phospholipids are vital to basic biological processes. They play roles in cellular energy production, cellular DNA information flow to RNA and to other proteins, intracellular communication (signal transduction), and in maintaining cell membrane integrity. The essential polyunsaturated fatty acids in LipoPhos Forte can “fludize” the cellular membranes, warding off the decline of cellular membrane repair function. This is of key importance in keeping our cells youthful, and supports the function of the liver, and the circulatory, nervous and immune systems.

How does EPL differ from regular phospholipids? In order to be absorbed into the lining of the small intestine, regular phospholipids need to be digested by the pancreatic enzyme phospholipase. The resulting compound (lysolecithin) then needs to be re-acidified back to phosphatides before it can use the lymphatic system to finally arrive in the blood stream. By contrast, EPL has a liposomal structure. Liposomes are tiny cell like structures, in the nanometer size range, that can get through the acidic stomach and then easily absorb from the intestinal tract. The oral delivery system of EPL offers both protection and delivery of their valuable nutrients, approaching the intravenous level of assimilation.

The liposomal structure is key to EPL’s effectiveness. Recent clinical tests have verified that EPL passes through biological membranes directly into the blood stream, effectively bridging the intestinal barrier. LipoPhos Forte is a nutritional supplement which not only offers the true health benefits of phospholipids, but also inherently contains its own transport mechanism! It is an enhanced form of concentrated beneficial phospholipids, optimized for absorption, and easy to take.

Each teaspoon (approx. 5 grams) contains:
Essential Phospholipids 900 mg
Other ingredients: Water, lecithin, natural alcohol 12%, natural anise oil.

Suggested Use: As a dietary supplement, one to two teaspoons a day (or 1 oz, once or twice a week) with liquid, or as directed by a healthcare practitioner.

Note: Refrigerate after opening. EPL is very well tolerated. No serious reactions have been reported. Occasionally, soft stools, diarrhea, constipation, and lack of appetite have been reported. Taking EPL with meals usually reduces these mild problems.

Selected References:

• Almazov VA, Freidlin IS, Krasil'nikova EI. [Use of lipostabil to correct lipid metabolism disorders in patients with ischemic heart disease] Kardiologiia. 1986 Feb; 26(2): 39-42. Russian.
• Blagosklonov AS, Nalivaiko ES, Bykov GA, Kaminka TIa, Khalilov EM. [Value of hemosorption and essential phospholipids in the complex treatment of patients with ischemic heart disease] Kardiologiia. 1986 Oct; 26(10): 35-8. Russian
• Coccheri S, Alessandri M, De Rosa V. Platelets and contact activation of blood clotting. Influence of some aggregation inhibitors. Acta Med Scand Suppl. 1971; 525: 253-6.
• Fasoli A, Therap. Select. Risk/Benefit Assess. Hypolipid. Drugs; G. Ricci et al. (Eds) Raven Press: New York 1982, 257-262.
• Hevelke G, Hogn T, Haase W, Bohlau V. [Results of a multicenter study with Lipostabil] Med Welt. 1980 Apr 18; 31(16): 598-602. Review. German.
• Horsch AK, Majolk I, Heuck CC, Gopfert E. [Effects of polyenylphosphatidylcholine (PPC) on serum lipids in patients with hyperlipoproteinemia. A double-blind study] Vasa. 1986; 15(3): 251-5. German.
• Knuechel F. [Comparative statistical study on the influence of lipostabil on serum proteins and lipoproteins] Med Nov. 1959 Sep 5; 36: 1652-3. German.
• Lata J, Dastych M Jr, Senkyrik M, et al. [Protective effect of essential phospholipids on liver injury due to total parenteral nutrition] Vnitr Lek. 2001 Sep; 47(9): 599-603. Czech
• Mel'chinskaia EN, Gromnatskii NI, et al. [Hypolipidemic effects of alisat and lipostabil in patients with diabetes mellitus] Ter Arkh. 2000; 72(8): 57-8. Russian.
• Skorepa J, Mares P, Todorovicova H. [Effect of polyene phospholipid on cholesterol metabolism in arteriosclerotic patients] Cas Lek Cesk. 1974; 113(26): 784-6. Czech.
• Varkonyi G. [A contribution to therapeutic effects of oral and intravenous administration of essential choline phospholipids] Z Gesamte Inn Med. 1962 Sep 15; 17: 830-4. German.
• Zeman M, Zak A, Stolba P. [The effect of polyene phosphatidylcholine administration on lipid metabolism and glucose tolerance in patients with hyperlipoproteinemia IIB] [Article in Czech] Sb Lek. 1995; 96(1): 43-8.
• Zierenberg O, Grundy SM. Intestinal absorption of polyenephos-phatidylcholine in man. J Lipid Res. 1982 Nov; 23(8): 1136-42.

Home | Books & Tapes | Nutrition Notebook | Our Privacy Policy | Contacts

Springboard products which are foods and/or foods for special dietary use, are not offered for the
diagnosis, cure, mitigation, treatment, or prevention of any disease or disorder nor have any statements herein been evaluated by
the Food and Drug Administration. We strongly encourage you to discuss topics of concern with your health care professional.

Copyright © 1998-2007 Springboard All rights reserved.

WebSite Designed and Managed by
AllBusNet.com
a subsidiary of Aerial Dynamics